New Approach to Type 2 Diabetes Treatment
A significant shift in the treatment of type 2 diabetes is on the horizon, with weight-loss medications potentially becoming available to patients much earlier than previously thought. This change marks one of the most substantial updates to diabetes care in over a decade. The National Institute for Health and Care Excellence (NICE) has proposed several recommendations that aim to revolutionize how patients are treated.
Under the new guidelines, individuals with type 2 diabetes may receive weight-loss drugs such as Ozempic at an earlier stage in their treatment journey, rather than waiting until other options have been exhausted. This approach moves away from the traditional one-size-fits-all method of starting all patients on the same medication. Instead, it emphasizes personalized care that focuses on preventing serious complications like heart failure and heart attacks.
One key aspect of the updated guidance is the recommendation to make SGLT-2 inhibitors a first-line treatment option. These newer drugs are designed to help manage blood sugar levels by aiding the kidneys in removing glucose through urine. However, NICE analysis revealed that these medications are currently under-prescribed, which could hinder their potential to save lives.
The guidelines suggest that patients who cannot tolerate metformin, the standard first-choice medication for type 2 diabetes, should begin treatment with an SGLT-2 inhibitor alone. This decision is based on evidence indicating that these drugs not only control blood sugar but also offer protection for the heart and kidneys. If widely adopted, this change could prevent nearly 22,000 deaths once 90% of patients are using these medications.
Professor Jonathan Benger, deputy chief executive and chief medical officer at NICE, emphasized the importance of this shift: “This guidance means more people will be offered medicines where it is right to do so to reduce their future risk of ill health. This represents a significant evolution in how we approach type 2 diabetes treatment.”
He further noted that the focus is now on a holistic view of a person’s health, particularly their cardiovascular and kidney health. By recommending certain medicines as part of initial treatment, NICE aims to prevent heart attacks, strokes, and other serious complications before they occur.
Tailored Care and Medication Access
In addition to the changes in treatment protocols, the new guidelines advocate for more tailored care for patients. Semaglutide, known as Ozempic, is among the medications that may be offered sooner. This drug is licensed in the UK for treating type 2 diabetes, while another version, Wegovy, is used by the NHS to assist obese individuals in losing weight.
Approximately 4.6 million people in the UK live with diabetes, with the majority having type 2. It is estimated that around 1.3 million more people may have undiagnosed type 2 diabetes. NICE analyzed records of 590,000 individuals and found that SGLT-2 inhibitors are under-prescribed, especially among women, older people, and black patients.
Professor Benger highlighted the need to address these prescribing gaps: “The guideline update published today will help to increase equitable uptake of SGLT-2 inhibitors, which we know can prevent serious health complications.”
Dr. Waqaar Shah, chairman of the guideline committee, added that people living in the most deprived areas would particularly benefit from universal access to these treatments. He noted that the recommendations could help reduce health inequalities while improving outcomes for everyone.
Additional Recommendations and Public Consultation
The draft guidance also includes different treatment approaches for patients with specific characteristics or health conditions. For example, adults with cardiovascular disease should be offered a triple therapy that includes weight-loss jabs. Meanwhile, adults diagnosed with type 2 diabetes before the age of 40 should be offered dual therapy before considering fat jabs. Patients with chronic kidney disease will receive tailored recommendations based on their kidney function.
A public consultation on the new NICE guidelines is open until October 2. Douglas Twenefour, head of clinical at Diabetes UK, welcomed the announcement, stating that it propels type 2 diabetes treatment into the 21st century. He emphasized that boosting access to newer treatments will be transformative for people with type 2 diabetes, ensuring the UK remains aligned with global advancements in care.
Twenefour also pointed out that many individuals with type 2 diabetes are not currently taking the most effective medication for them, putting them at risk of severe complications. He noted that tailoring treatment based on individual risk could protect thousands against heart attacks and kidney disease.
Overall, these new guidelines could significantly ease the burden of living with type 2 diabetes while addressing inequities in treatment and outcomes.
